Status:
COMPLETED
Erectile Dysfunction/Prostate/RT/Androgen
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The optimal duration of hormonal therapy is yet to be determined in the treatment of locally advanced carcinoma of the prostate. The RTOG performed a trial of 4 months of neoadjuvant and concurrent ho...
Eligibility Criteria
Inclusion
- Patients with clinical stage T1-T4 carcinoma of the prostate
- Must have undergone radical radiation and at least 2 years of Pharmacological androgen ablation.Pharmacological androgen ablation may include: LHRH-agonists with or without Non-steroidal androgen ablation, Steroidal Anti-androgens, Progestational agents, and Cypoterone (Androcur).
- Must be currently 6 months or more after their last injection of LHRH-agonists if it was being given every 3 months or 4 months or more after their last injection, if it was being given monthly. If the patient was on oral androgen ablation agent, they must be off this medication for a period of at least 4 months.
- currently off hormonal therapy
- Able to sign the consent form and fill out questionnaire used in the study.
Exclusion
- No patients who have been treated, or are currently being treated with Bicalutamide
- no previous orchidectomy.
Key Trial Info
Start Date :
March 1 2000
Trial Type :
INTERVENTIONAL
End Date :
April 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00242138
Start Date
March 1 2000
End Date
April 1 2004
Last Update
February 9 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9